Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. (RXDX) priced its initial public offering on Mar 12, 2021 at $19.00 per share, within its $18.00–$19.00 range, raising $190M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $707.8M. Leerink Partners was lead-left underwriter, joined by Credit Suisse, Stifel and Guggenheim. Latham & Watkins advised the company and Davis Polk advised the underwriters.

Prometheus Biosciences, Inc. is a biotechnology company taking a precision medicine approach to therapeutics and companion diagnostics for inflammatory bowel disease. Its Prometheus360 platform draws on a large gastrointestinal bioinformatics database, and its lead candidate, PRA023, is an antibody blocking TL1A.

Status

IPO

Ticker

RXDX

Exchange

Nasdaq Global Select

Priced

Mar 12, 2021

IPO price

$19.00

Price range

$18.00–$19.00

Raised

$190M

Market cap at IPO price

$707.8M

First filed

Feb 19, 2021

Underwriters

Leerink Partners, Credit Suisse, Stifel and Guggenheim

Company counsel

Latham & Watkins

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.